Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5311-5322

  Wong, Iris L K ^a   Chan, Kin Fai ^a   Ka, Hing Tsang ^a   Chi, Yin Lam ^a   Zhao, Yunzhe ^a   Tak, Hang Chan ^a,b   Chow, Larry Ming Cheung ^a,b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b State Key Laboratory of Chinese Medicine and Molecular Pharmacology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,16 BIS[4' [(6 METHYL) 4H CHROMEN 4 ON 2 YL]PHENYL] 1,4,7,10,13,16 HEXAOXAHEXADECANE; 1,16 BIS[4' [(7 METHYL) 4H CHROMEN 4 ON 2 YL]PHENYL] 1,4,7,10,13,16, HEXAOXAHEXADECANE; 1,19 BIS[4' [(6 METHYL) 4H CHROMEN 4 ON 2 YL]PHENYL] 1,4,7,10,13,16,19 HEPTAOXANONADECANE; 1,19 BIS[4' [(7 METHYL) 4H CHROMEN 4 ON 2 YL]PHENYL] 1,4,7,10,13,16,19 HEPTAOXANONADECANE; APIGENIN; DOXORUBICIN; ETHYLENE GLYCOL; ETOPOSIDE; FLAVONOID; HOMODIMER; HYDROXYL GROUP; METHYL GROUP; MULTIDRUG RESISTANCE PROTEIN 1; PROBENECID; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

APIGENIN; BINDING, COMPETITIVE; CELL LINE, TUMOR; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; HUMANS; HYDROXIDES; INTRACELLULAR SPACE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69949099322     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900194w     Document Type: Article

References (72)

1. Bakos, E.; Hegedus, T.; Hollo, Z.; Welker, E.; Tusnady, G. E.; Zaman, G. J.; Flens, M. J.; Varadi, A.; Sarkadi, B. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J. Biol. Chem. 1996, 271, 12322-12326.
2. Hipfner, D. R.; Almquist, K. C.; Leslie, E. M.; Gerlach, J. H.; Grant, C. E.; Deeley, R. G.; Cole, S. P. Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. 1997, 272, 23623-23630.
3. Raab-Graham, K. F.; Cirilo, L. J.; Boettcher, A. A.; Radeke, C. M.; Vandenberg, C. A. Membrane topology of the amino-terminal region of the sulfonylurea receptor. J. Biol. Chem. 1999, 274, 29122-29129.
4. Bakos, E.; Evers, R.; Calenda, G.; Tusnady, G. E.; Szakacs, G.; Varadi, A.; Sarkadi, B. Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J. Cell Sci. 2000, 113 (Pt 24), 4451-4461. (Pubitemid 32117906)
5. Bakos, E.; Evers, R.; Szakacs, G.; Tusnady, G. E.; Welker, E.; Szabo, K.; de Haas, M.; van Deemter, L.; Borst, P.; Varadi, A.; Sarkadi, B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 1998, 273, 32167-32175.
6. Gao, M.; Yamazaki, M.; Loe, D. W.; Westlake, C. J.; Grant, C. E.; Cole, S. P.; Deeley, R. G. Multidrug resistance protein. Identification of regions required for active transport of leukotriene C4. J. Biol. Chem. 1998, 273, 10733-10740.
7. Cole, S.; Bhardwaj, G.; Gerlach, J.; Mackie, J.; Grant, C.; Almquist, K.; Stewart, A.; Kurz, E.; Duncan, A.; Deeley, R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654. (Pubitemid 23012438)
8. Cole, S. P.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910. (Pubitemid 24375226)
9. Grant, C. E.; Valdimarsson, G.; Hipfner, D. R.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994, 54, 357-361.
10. Zaman, G. J.; Flens, M. J.; van Leusden, M. R.; de Haas, M.; Mulder, H. S.; Lankelma, J.; Pinedo, H. M.; Scheper, R. J.; Baas, F.; Broxterman, H. J.; et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U.S.A 1994, 91, 8822-8826.
11. Leier, I.; Jedlitschky, G.; Buchholz, U.; Center, M.; Cole, S. P.; Deeley, R. G.; Keppler, D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J. 1996, 314, 433-437. (Pubitemid 26075650)
12. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S. P.; Deeley, R. G.; Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810.
13. Loe, D. W.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem. 1996, 271, 9683-9689.
14. Loe, D. W.; Almquist, K. C.; Deeley, R. G.; Cole, S. P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 1996, 271, 9675-9682.
15. Mao, Q.; Deeley, R. G.; Cole, S. P. Functional reconstitutionof substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J. Biol. Chem. 2000, 275, 34166-34172.
16. Muller, M.; Meijer, C.; Zaman, G. J.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G.; Jansen, P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A 1994, 91, 13033-13037.
17. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 1992, 17, 463-468.
18. Oude Elferink, R. P.; Meijer, D. K.; Kuipers, F.; Jansen, P. L.; Groen, A. K.; Groothuis, G. M. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1995, 1241, 215-268.
19. Loe, D. W.; Deeley, R. G.; Cole, S. P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998, 58, 5130-5136.
20. Rappa, G.; Lorico, A.; Flavell, R. A.; Sartorelli, A. C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 1997, 57, 5232-5237.
21. Renes, J.; de Vries, E. G.; Nienhuis, E. F.; Jansen, P. L.; Muller, M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 1999, 126, 681-688.
22. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
23. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670.
24. Cole, S.; Deeley, R. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 2006, 27, 438-446.
25. Boumendjel, A.; Baubichon-Cortay, H.; Trompier, D.; Perrotton, T.; Di Pietro, A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 2005, 25, 453-472.
26. Norman, B. H. Inhibitors of MRP1-mediated multidrug resistance. Drugs Future 1998, 23, 1001-1013.
27. Duffy, C. P.; Elliott, C. J.; O'Connor, R. A.; Heenan, M. M.; Coyle, S.; Cleary, I. M.; Kavanagh, K.; Verhaegen, S.; O'Loughlin, C. M.; NicAmhlaoibh, R.; Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34, 1250-1259. (Pubitemid 28342118)
28. Gollapudi, S.; Kim, C. H.; Tran, B. N.; Sangha, S.; Gupta, S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein- overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother. Pharmacol. 1997, 40, 150-158.
29. Evers, R.; de Haas, M.; Sparidans, R.; Beijnen, J.; Wielinga, P. R.; Lankelma, J.; Borst, P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 2000, 83, 375-383. (Pubitemid 30453579)
30. Draper, M. P.; Martell, R. L.; Levy, S. B. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 1997, 75, 810-815. (Pubitemid 27110695)
31. Nakano, R.; Oka, M.; Nakamura, T.; Fukuda, M.; Kawabata, S.; Terashi, K.; Tsukamoto, K.; Noguchi, Y.; Soda, H.; Kohno, S. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem. Biophys. Res. Commun. 1998, 251, 307-312.
32. Gekeler, V.; Ise, W.; Sanders, K. H.; Ulrich, W. R.; Beck, J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 1995, 208, 345-352.
33. Barrand, M. A.; Rhodes, T.; Center, M. S.; Twentyman, P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer 1993, 29A, 408-415.
34. Dantzig, A. H.; Shepard, R. L.; Pratt, S. E.; Tabas, L. B.; Lander, P. A.; Ma, L.; Paul, D. C.; Williams, D. C.; Peng, S. B.; Slapak, C. A.; Godinot, N.; Perry, W. L., III. Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters. Biochem. Pharmacol. 2004, 67, 1111-1121.
35. Norman, B. H.; Lander, P. A.; Gruber, J. M.; Kroin, J. S.; Cohen, J. D.; Jungheim, L. N.; Starling, J. J.; Law, K. L.; Self, T. D.; Tabas, L. B.; Williams, D. C.; Paul, D. C.; Dantzig, A. H. Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett. 2005, 15, 5526-5530.
36. Norman, B. H.; Gruber, J. M.; Hollinshead, S. P.; Wilson, J. W.; Starling, J. J.; Law, K. L.; Self, T. D.; Tabas, L. B.; Williams, D. C.; Paul, D. C.; Wagner, M. M.; Dantzig, A. H. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett. 2002, 12, 883-886.
37. Hooijberg, J. H.; Broxterman, H. J.; Heijn, M.; Fles, D. L.; Lankelma, J.; Pinedo, H. M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 1997, 413, 344-348. (Pubitemid 27353297)
38. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 2003, 31, 11-15. (Pubitemid 36735252)
39. Leslie, E. M.; Mao, Q.; Oleschuk, C. J.; Deeley, R. G.; Cole, S. P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol. Pharmacol. 2001, 59, 1171-1180.
40. Nguyen, H.; Zhang, S.; Morris, M. E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 2003, 92, 250-257.
41. Trompier, D.; Baubichon-Cortay, H.; Chang, X. B.; Maitrejean, M.; Barron, D.; Riordon, J. R.; Di Pietro, A. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell. Mol. Life Sci. 2003, 60, 2164-2177.
42. van Zanden, J. J.; Geraets, L.; Wortelboer, H. M.; van Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem. Pharmacol. 2004, 67, 1607-1617.
43. van Zanden, J. J.; Wortelboer, H. M.; Bijlsma, S.; Punt, A.; Usta, M.; Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H. Quantitative structure-activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 2005, 69, 699-708.
44. Versantvoort, C. H.; Broxterman, H. J.; Lankelma, J.; Feller, N.; Pinedo, H. M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 1994, 48, 1129-1136.
45. Bansal, T.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 2009, 12, 46-78.
46. Duenas, M.; Gonzalez-Manzano, S.; Gonzalez-Paramas, A.; Santos-Buelga, C. Antioxidant evaluation of O-methylated metabolites of catechin, epicatechin and quercetin. J. Pharm. Biomed. Anal. 2009, 10.1016/j.jpba.2009.004.007.
47. Garcia-Lafuente, A.; Guillamon, E.; Villares, A.; Rostagno, M. A.; Martinez, J. A. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 2009, 21, 21.
48. Song, J. M.; Park, K. D.; Lee, K. H.; Byun, Y. H.; Park, J. H.; Kim, S. H.; Kim, J. H.; Seong, B. L. Biological evaluation of anti-influenza viral activity of semisynthetic catechin derivatives. Antiviral Res. 2007, 76, 178-185.
49. Hirano, T.; Oka, K.; Akiba, M. Effects of synthetic and naturally occurring flavonoids on Na+,K+-ATPase: aspects of the structure-activity relationship and action mechanism. Life Sci. 1989, 45, 1111-1117. (Pubitemid 19229498)
50. Jinsart, W.; Ternai, B.; Polya, G. M. Inhibition of myosin light chain kinase, cAMP-dependent protein kinase, protein kinase C and of plant Ca(2+)-dependent protein kinase by anthraquinones. Biol. Chem. Hoppe Seyler 1992, 373, 903-910.
51. Chan, K. F.; Zhao, Y.; Burkett, B. A.; Wong, I. L.; Chow, L. M.; Chan, T. H. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells. J. Med. Chem. 2006, 49, 6742-6759.
52. Chan, K. F.; Zhao, Y.; Chow, T. W.; Yan, C. S.; Ma, D. L.; Burkett, B. A.; Wong, I. L.; Chow, L. M.; Chan, T. H. Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships. ChemMedChem 2009, 4, 594-614.
53. Wong, I. L.; Chan, K. F.; Burkett, B. A.; Zhao, Y.; Chai, Y.; Sun, H.; Chan, T. H.; Chow, L. M. Flavonoid dimers as bivalent modulators for pentamidine and sodium stiboglucanate resistance in leishmania. Antimicrob. Agents Chemother. 2007, 51, 930-940.
54. Wong, I. L.; Chan, K. F.; Zhao, Y.; Chan, T. H.; Chow, L. M. Quinacrine and a novel apigenin dimer can synergistically increase the pentamidine susceptibility of the protozoan parasite Leishmania. J. Antimicrob. Chemother. 2009, 63, 1179-1190.
55. Hooijberg, J.; Broxterman, H.; Kool, M.; Assaraf, Y.; Peters, G.; Noordhuis, P.; Scheper, R.; Borst, P.; Pinedo, H.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59, 2532-2535. (Pubitemid 29269093)
56. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discovery 2006, 5, 219-234.
57. Jonsson-Videsater, K.; Andersson, G.; Bergh, J.; Paul, C. Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin. Ther. Drug Monit. 2003, 25, 331-339.
58. Cullen, K. V.; Davey, R. A.; Davey, M. W. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem. Pharmacol. 2001, 62, 417-424.
59. Sumizawa, T.; Chen, Z. S.; Chuman, Y.; Seto, K.; Furukawa, T.; Haraguchi, M.; Tani, A.; Shudo, N.; Akiyama, S. I. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol. Pharmacol. 1997, 51, 399-405.
60. Chen, Z. S.; Aoki, S.; Komatsu, M.; Ueda, K.; Sumizawa, T.; Furukawa, T.; Okumura, H.; Ren, X. Q.; Belinsky, M. G.; Lee, K.; Kruh, G. D.; Kobayashi, M.; Akiyama, S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int. J. Cancer 2001, 93, 107-113. (Pubitemid 32539509)
61. van Zanden, J. J.; de Mul, A.; Wortelboer, H. M.; Usta, M.; van Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol. 2005, 69, 1657-1665.
62. Yang, Z.; Horn, M.; Wang, J.; Shen, D. D.; Ho, R. J. Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci 2004, 6, E8.
63. Burg, D.; Wielinga, P.; Zelcer, N.; Saeki, T.; Mulder, G. J.; Borst, P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol. Pharmacol. 2002, 62, 1160-1166.
64. de Jong, M. C.; Slootstra, J. W.; Scheffer, G. L.; Schroeijers, A. B.; Puijk, W. C.; Dinkelberg, R.; Kool, M.; Broxterman, H. J.; Meloen, R. H.; Scheper, R. J. Peptide transport by the multidrug resistance protein MRP1. Cancer Res. 2001, 61, 2552-2557. (Pubitemid 32685838)
65. Iseki, K.; Sugawara, M.; Sato, K.; Naasani, I.; Hayakawa, T.; Kobayashi, M.; Miyazaki, K. Multiplicity of the H+-dependent transport mechanism of dipeptide and anionic beta-lactam antibiotic Ceftibuten in rat intestinal brush-border membrane. J. Pharmacol. Exp. Ther. 1999, 289, 66-71.
66. Wang, E. J.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta 2000, 1481, 63-74.
67. Sauna, Z. E.; Andrus, M. B.; Turner, T. M.; Ambudkar, S. V. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry 2004, 43, 2262-2271.
68. Pires, M. M.; Hrycyna, C. A.; Chmielewski, J. Bivalent probes of the human multidrug transporter P-glycoprotein. Biochemistry 2006, 45, 11695-11702. (Pubitemid 44454017)
69. Pires, M. M.; Emmert, D.; Hrycyna, C. A.; Chmielewski, J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol. 2009, 75, 92-100.
70. Zhou, S. F.; Wang, L. L.; Di, Y. M.; Xue, C. C.; Duan, W.; Li, C. G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 2008, 15, 1981-2039.
71. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
72. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.